The Medical University of Vienna has filed a new patent application for extended protection of T20K, included in Cyxone’s license agreement
Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the Medical University of Vienna has filed a new patent application for extended protection of T20K in multiple sclerosis (MS). The patent is included in Cyxone’s license agreement with the Medical University and is entitled “Cyclotides in combination with kappa opioid receptor ligands for multiple sclerosis therapy”.With this extended patent, Cyxone will have more therapeutic options for their cyclotides, a wider patent protection and a new priority date. Contact Ola Skanung, interim CEO & CFO Tel: